Showing results (271-280 of 363) with videos related to

Sort By:
Pageof 37
Dermatitis : Contact, Atopic, Occupational, Drug|July 22, 2010
Quantitative risk assessment of contact sensitization: clinical data to assess utility of the modelAnne Marie Api, Donald Belsito, David Bickers, et al.
Particle and Fibre Toxicology|March 13, 2026
A quantitative definition for poorly soluble particlesLan Ma-Hock, Heidi Stratmann, Matthias Hufnagel, et al.
Ecotoxicology and Environmental Safety|April 1, 1997
Considerations on genetic and environmental factors that contribute to resistance or sensitivity of mammals including humans to toxicity of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) and related compounds. Part 1: Genetic factors affecting the toxicity of TCDDH J Geyer, K W Schramm, I Scheunert, et al.
Regulatory Toxicology and Pharmacology : RTP|July 30, 2011
Classification of skin sensitizing substances: a comparison between approaches used by the DFG-MAK Commission and the European Union legislationH Lessmann, W Uter, T L Diepgen, et al.
German Medical Science : GMS E-Journal|August 2, 2013
The German quality indicators in intensive care medicine 2013--second editionJan-Peter Braun, Oliver Kumpf, Maria Deja, et al.
German Medical Science : GMS E-Journal|August 11, 2017
Quality indicators in intensive care medicine for Germany - third edition 2017Oliver Kumpf, Jan-Peter Braun, Alexander Brinkmann, et al.
European Journal of Cancer (Oxford, England : 1990)|January 31, 2002
Patient preference and pharmacokinetics of oral modulated UFT versus intravenous fluorouracil and leucovorin: a randomised crossover trial in advanced colorectal cancerM M Borner, P Schoffski, R de Wit, et al.
International Journal of Integrated Care|May 12, 2025
Development of a Person-Centred Coordinated Care Pathway in Swedish Healthcare for Low Back PainAllan Abbott, Malin Forsbrand, Thomas Torstensson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 18, 2000
Phase I and pharmacological study of weekly administration of the polyamine synthesis inhibitor SAM 486A (CGP 48 664) in patients with solid tumors. European Organization for Research and Treatment of Cancer Early Clinical Studies GroupF A Eskens, G A Greim, C van Zuylen, et al.
Regulatory Toxicology and Pharmacology : RTP|October 19, 2020
Updating exposure assessment for skin sensitization quantitative risk assessment for fragrance materialsAnne Marie Api, David Basketter, James Bridges, et al.
Pageof 37